AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23557023
Drug: Budesonide/formoterol (Symbicort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (Symbicort SMART(®), 160/4.5 μg) twice daily plus as needed
Trial: 23557757
Drug: Metformin (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,500 mg/day) for 16 weeks
Trial: 23557757
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-insulin-resistant women), n = 5
Trial: 23557865
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia with fentanyl
Trial: 23557865
Drug: Genetic polymorphisms
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic polymorphisms (OPRM1 118A>G, ABCB1 2677G>A/T, ABCB1 3435C>T, CYP3A4*18, CYP3A5*3)
Trial: 23558394
Drug: Citalopram (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20-40 mg/day) during level 1 treatment
Trial: 23558394
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to sertraline, sustained-release bupropion, or extended-release venlafaxine or augmentation with sustained-release bupropion or buspirone during level 2 treatment
Trial: 23558394
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment responders
Trial: 23558394
Drug: Second-step treatment
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Second-step treatment responders
Trial: 23558394
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with treatment resistance
Trial: 23559086
Drug: Oral macimorelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral macimorelin
Trial: 23560574
Drug: NeuroBlate System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeuroBlate System (laser interstitial thermal therapy)
Trial: 23563210
Drug: Bevacizumab with
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab with chemotherapy (docetaxel, cyclophosphamide, followed by doxorubicin) every 3 weeks for 4 cycles, then surgery, followed by bevacizumab every 3 weeks for 9 cycles.
Trial: 23564195
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy for CAP patients (mean duration = 11.1 days)
Trial: 23564195
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy for AECOPD patients (mean duration = 8.9 days)
Trial: 23565181
Drug: Rifaximin 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg BID for 8 weeks
Trial: 23565931
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment for hyperglycaemia
Trial: 23565931
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment for dyslipidaemia
Trial: 23565931
Drug: Treatment targets
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment targets for haemoglobin A1c, LDL, HDL, non-HDL cholesterol, systolic BP, BMI, waist circumference
Trial: 23566357
Drug: Minocycline (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (1.4 mg/kg for six months)
Trial: 23569312
Drug: PD0332991 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD0332991 200 mg orally once per day for 14 consecutive days in 21-day cycles
Trial: 23569315
Drug: Trastuzumab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (4 mg/kg loading, then 2 mg/kg once per week) and lapatinib (1000 mg once per day for 12 weeks)
Trial: 23569315
Drug: Trastuzumab and
RxNorm normalized name: pertuzumab and trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab and lapatinib with letrozole (plus LHRH agonist if premenopausal) for ER-positive tumors
Trial: 23576625
Drug: CERE-120 (AAV2-neurturin)
RxNorm normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: CERE-120 (DB05637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CERE-120 (AAV2-neurturin) administered bilaterally to the substantia nigra and putamen
Trial: 23577182
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg twice daily for 4 weeks
Trial: 23581634
Drug: HuCNS-SC transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuCNS-SC transplantation (low-dose)
Trial: 23581634
Drug: HuCNS-SC transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuCNS-SC transplantation (high-dose)
Trial: 23582881
Drug: Everolimus 10mg
RxNorm normalized name: EVEROLIMUS 10MG TAB
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 10mg daily
Trial: 23583440
Drug: Trametinib 2mg
RxNorm normalized name: TRAMETINIB 2MG ORAL TAB
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib 2mg daily with standard gemcitabine dosing (1000 mg/m(2) IV Days 1, 8, and 15 of 28-day cycles)
Trial: 23583440
Drug: Standard gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard gemcitabine dosing (1000 mg/m(2) IV Days 1, 8, and 15 of 28-day cycles)
Trial: 23584252
Drug: HZ/su vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZ/su vaccine (two doses according to a 0, 2-month schedule)
Trial: 23586347
Drug: Initial antibiotic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antibiotic treatment modification
Trial: 23586347
Drug: Streamlining (de-escalation)
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streamlining (de-escalation) of therapy
Trial: 23587148
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of adjuvant FOLFOX treatment
Trial: 23588536
Drug: Pentostatin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentostatin 1.5 mg/m(2)/day intravenously on days 1-3 of each 14-day cycle
Trial: 23588536
Drug: Pentostatin 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentostatin 0.75 mg/m(2) after dose reduction
Trial: 23588536
Drug: Pentostatin treatment
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentostatin treatment
Trial: 23589215
Drug: AZD8931 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 40 mg bid
Trial: 23589215
Drug: AZD8931 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 80 mg bid
Trial: 23589215
Drug: AZD8931 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 160 mg bid
Trial: 23589215
Drug: AZD8931 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 240 mg bid
Trial: 23589215
Drug: AZD8931 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 300 mg bid
Trial: 23589215
Drug: AZD8931 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 (all doses)
Trial: 23589315
Drug: Cetuximab (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (initial dose of 400 mg/m(2) on day 1 followed by 250 mg/m(2) weekly)
Trial: 23589410
Drug: Telehealth interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telehealth interventions for mental health treatment
Trial: 23590701
Drug: PB 500
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB 500 mg twice daily with vitamin D3 5000 IU once daily (Group-II)
Trial: 23590701
Drug: PB 250
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB 250 mg twice daily (Group-I)
Trial: 23590701
Drug: PB 500
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB 500 mg twice daily (Group-I)
Trial: 23590701
Drug: PB 500
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB 500 mg twice daily (Group-IV)
Trial: 23590701
Drug: PB 500
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB 500 mg twice daily (Group-I), PB 500 mg twice daily (Group-II), vitamin D3 5000 IU once daily (Group-V)
Trial: 23591447
Drug: U3-1287 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U3-1287 (20 mg/kg every 2 weeks)
Trial: 23592303
Drug: Raised serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raised serum level of C-reactive protein (over 240 mg/l) during the first attack
Trial: 23592699
Drug: Preoperative docetaxel/platin/fluoropyrimidine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative docetaxel/platin/fluoropyrimidine-based chemotherapy
Trial: 23593142
Drug: ORMD-0801 oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORMD-0801 oral insulin capsules (8 mg insulin), self-administered three times daily before meals
Trial: 23593305
Drug: High levels
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High levels of CC-chemokine ligand 21
Trial: 23596180
Drug: Oral disposition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral disposition index
Trial: 23597147
Drug: Treprostinil diethanolamine
RxNorm normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treprostinil diethanolamine SR (2 mg and 4 mg doses, twice daily)
Trial: 23598171
Drug: Crizotinib 280
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib 280 mg/m(2) twice daily
Trial: 23602668
Drug: MEDI-534 vaccine
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-534 vaccine at 10(6)TCID50
Trial: 23602777
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg daily with HPR (PRU ≥234)
Trial: 23604435
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg isotopically labeled cyanidin-3-glucoside
Trial: 23609828
Drug: HLA class
RxNorm normalized name: HLA class I antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA class I haplotype (HLA-A2) peptide vaccine
Trial: 23609828
Drug: HLA class
RxNorm normalized name: HLA class I antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA class II haplotype (DR4, DP4) peptide vaccine
Trial: 23610374
Drug: Virus-specific T
RxNorm normalized name: Allogeneic JC polyomavirus-specific T-cell therapy
DrugBank: CE-VST01-JC (DB17190)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virus-specific T cell (VST) lines administered to patients (n = 50)
Trial: 23611709
Drug: Zenith p-branch
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zenith p-branch device (standard fenestrated endovascular graft); off-the-shelf design used for treatment.
Trial: 23611902
Drug: Interactive media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive media treatment for depression (6 sessions of problem-solving therapy)
Trial: 23611902
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control group (no treatment for 6 weeks)
Trial: 23612920
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of autologous bone marrow-derived progenitor cells (BMC)
Trial: 23612920
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified, but implied as patients not receiving BMC therapy)
Trial: 23613128
Drug: LY6K-177 peptide
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY6K-177 peptide vaccine emulsified with Montanide ISA 51
Trial: 23613128
Drug: LY6K-177 peptide
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY6K-177 peptide vaccine
Trial: 23613521
Drug: 5-azacytidine (AZA)
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5-azacytidine (AZA) 75 mg/m(2) intravenously daily for 7 days and sorafenib 400 mg orally twice daily continuously; cycles were repeated at ~1-month intervals
Trial: 23615181
Drug: Oral ridaforolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ridaforolimus (40 mg QDx5/wk) combined with intravenous bevacizumab (10 mg/kg Q2wk or 15 mg/kg Q3wk)
Trial: 23615181
Drug: Intravenous bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous bevacizumab (10 mg/kg Q2wk or 15 mg/kg Q3wk)
Trial: 23617626
Drug: Intensive malaria
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive malaria screening and prompt treatment
Trial: 23617744
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy as per evidence-based guidelines for stroke prevention in AF
Trial: 23620058
Drug: Alginate-encapsulated human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate-encapsulated human islet cell implants
Trial: 23621514
Drug: SNS01 (Ectoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNS01 (Ectoin Rhinitis nasal spray)
Trial: 23623397
Drug: Eculizumab 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab 600 mg intravenous weekly for 4 weeks, 900 mg in the fifth week, and then 900 mg every 2 weeks for 48 weeks.
Trial: 23623559
Drug: Sequential FISH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential FISH analyses of immunomagnetically enriched CD34+ peripheral blood cells
Trial: 23624172
Drug: Alternative intervention
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative intervention focused on oral health
Trial: 23624209
Drug: CD30 positive
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CD30 positive cases after chemotherapy
Trial: 23624209
Drug: CD30 negative
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CD30 negative cases after chemotherapy
Trial: 23624209
Drug: After first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After first line treatment in CD30 positive cases
Trial: 23624209
Drug: After first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After first line treatment in CD30 negative cases
Trial: 23624993
Drug: Liraglutide (0.6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (0.6, 1.2, or 1.8 mg daily for 12 weeks)
Trial: 23626752
Drug: Moxifloxacin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin treatment
Trial: 23626901
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (r-hGH) therapy (0.033 mg/kg daily for 4 weeks)
Trial: 23628375
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) use
Trial: 23629714
Drug: Azithromycin (AZI)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (AZI) 500 mg once a day for 3 days
Trial: 23630200
Drug: Cediranib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib (30 mg once daily in 28-day cycles)
Trial: 23631460
Drug: Control (anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (anesthetic agents only)
Trial: 23632474
Drug: Neratinib 240
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 240 mg once daily plus intravenous paclitaxel 80 mg m(-2) on days 1, 8, and 15 of each 28-day cycle
Trial: 23632636
Drug: Palmitic acid
RxNorm normalized name: Palmitic Acid
DrugBank: Palmitic Acid (DB03796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmitic acid (PA) treatment
Trial: 23632636
Drug: TNFα treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFα treatment
Trial: 23632636
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PA and TNFα treatment
Trial: 23632904
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (0.03-0.06 mg/kg/day) for >12 months (mean duration 4.1 years)
Trial: 23633404
Drug: H5 DNA
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H5 DNA prime followed by H5N1 monovalent inactivated vaccine boost at intervals of 4, 8, 12, 16, or 24 weeks
Trial: 23633404
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of H5N1 monovalent inactivated vaccine
Trial: 23633404
Drug: H5 DNA
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H5 DNA prime followed by H5N1 monovalent inactivated vaccine boost at intervals of ≥12 weeks
Trial: 23636448
Drug: Pazopanib 400
RxNorm normalized name: PAZOPanib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 400 mg plus ketoconazole 400 mg once daily for 5 days after 7 days of pazopanib 400 mg alone.
Trial: 23636448
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg plus esomeprazole 40 mg once daily for 5 days after 7 days of pazopanib 800 mg alone.
Trial: 23636645
Drug: Cold cap
RxNorm normalized name: 666 Cold Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold cap (CC)
Trial: 23636645
Drug: Cooling (PAX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling (PAX and CC combined)
Trial: 23636645
Drug: PAX and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAX and CC
Trial: 23636668
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LDH ≥1.5 × ULN with clinical symptoms (abdominal pain, chest pain, dyspnea, hemoglobinuria)
Trial: 23637051
Drug: Deferasirox administration
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox administration modes during assessment phase
Trial: 23639146
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (extended-release), robust dosing, duration up to 12 months
Trial: 23642526
Drug: FEC (5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC (5-fluorouracil 600 mg/m(2), epirubicin 90 mg/m(2), cyclophosphamide 600 mg/m(2)) followed by weekly paclitaxel (80 mg/m(2)) with bevacizumab 10 mg/kg every 2 weeks
Trial: 23642625
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation with paclitaxel 135 mg/m(2) and carboplatin AUC 5 every 3 weeks for 3 cycles
Trial: 23642625
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation with paclitaxel/carboplatin
Trial: 23643595
Drug: Copeptin levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copeptin levels <14 pmol/L combined with cardiac troponin I (cTnI) <99th percentile
Trial: 23643595
Drug: Copeptin >14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copeptin >14 pmol/L
Trial: 23644082
Drug: Transcatheter valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter valve therapy (TVT) devices
Trial: 23645402
Drug: Profiles of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Profiles of exhaled volatile organic compounds (VOCs)
Trial: 23645694
Drug: escalated dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escalated dose subcutaneous alemtuzumab (starting at 30 mg three times per week, escalating to 90 mg weekly) with rituximab (375 mg/m² weekly)
Trial: 23645694
Drug: escalated dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escalated dose subcutaneous alemtuzumab with rituximab
Trial: 23646111
Drug: Stable combination
RxNorm normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable combination antiretroviral therapy
Trial: 23646111
Drug: Stable combination
RxNorm normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable combination antiretroviral therapy (Caucasian ethnicity)